Podcasts about Harvard Medical School

Most people don't realize that what happens in the mouth can ripple through the whole body. The balance of the oral microbiome—the community of bacteria living in our mouths—can either protect us or trigger widespread inflammation that affects the heart, joints, and brain. Hidden dental infections or mercury fillings can quietly drive fatigue, autoimmune issues, or dementia—and fixing the mouth often helps the rest of the body heal, too. The good news is that with simple steps like eating whole foods (often removing gluten), cleaning the mouth well, and breathing through the nose, we can protect both our smile and our overall health. When we care for the mouth as part of the body, lasting wellness becomes possible from the inside out. In this episode, Dr. Todd LePine, Dr. Elizabeth Boham, James Nestor, and I talk about how a healthy mouth microbiome is a key to whole-body wellness. Dr. Todd LePine graduated from Dartmouth Medical School and is Board Certified in Internal Medicine, specializing in Integrative Functional Medicine. He is an Institute for Functional Medicine Certified Practitioner. Prior to joining The UltraWellness Center, he worked as a physician at Canyon Ranch in Lenox, MA, for 10 years. Dr. LePine's focus at The UltraWellness Center is to help his patients achieve optimal health and vitality by restoring the natural balance to both the mind and the body. His areas of interest include optimal aging, bio-detoxification, functional gastrointestinal health, systemic inflammation, autoimmune disorders, and the neurobiology of mood and cognitive disorders. Dr. Elizabeth Boham is Board Certified in Family Medicine from Albany Medical School, and she is an Institute for Functional Medicine Certified Practitioner and the Medical Director of The UltraWellness Center. Dr. Boham lectures on a variety of topics, including Women's Health and Breast Cancer Prevention, insulin resistance, heart health, weight control and allergies. She is on the faculty for the Institute for Functional Medicine. James Nestor is an author and journalist who has written for Scientific American, Outside, The New York Times, and more. His book, Breath: The New Science of a Lost Art, was an instant New York Times and London Sunday Times bestseller. Breath explores how the human species has lost the ability to breathe properly—and how to get it back. Breath spent 18 weeks on the New York Times bestseller list in the first year of release, and will be translated into more than 30 languages. Breath was awarded the Best General Nonfiction Book of 2020 by the American Society of Journalists and Authors, and was nominated for Best Science Book of 2021 by the Royal Society. Nestor has spoken at Stanford Medical School, Yale School of Medicine, Harvard Medical School, The United Nations, Global Classroom, and appeared on more than 60 radio and television shows, including Fresh Air with Terry Gross, the Joe Rogan Show, and more. He lives and breathes in San Francisco. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN to save 15%. Full-length episodes can be found here:The Functional Medicine Approach To Oral Health Getting Rid of Cold Sores and Canker Sores The Power Of Breath As Medicine

In this Season 14 review (episode 376) Andrea Samadi revisits highlights from her interview with Dr. John Ratey about the science of exercise, nutrition, and social connection for brain health and longevity. The episode explains Peter Attia's rule for foundational fitness, warns against sugar dependence and fat phobia, and presents the three biggest levers for healthy aging: exercise, diet, and social connection, plus practical tips to track and apply these habits. Takeaway: prioritize consistent movement, whole foods, and meaningful connection to boost mood, memory, and overall well-being. On today's episode #376, we review PART 2 of our 2021 interview with Dr. John Ratey and will learn: ✔  3 Science-backed keys to brain health: Exercise, Nutrition and Connection ✔ What is Attia's Rule that allows us to dive deep into diet and nutrition? ✔ Practical Tips for improving consistent movement, our diet and social connection to boost overall well-being and brain health.  Welcome back to SEASON 14 of The Neuroscience Meets Social and Emotional Learning Podcast, where we connect the science-based evidence behind social and emotional learning and emotional intelligence training for improved well-being, achievement, productivity and results—using what I saw as the missing link (since we weren't taught this when we were growing up in school), the application of practical neuroscience. I'm Andrea Samadi, and seven years ago, launched this podcast with a question I had never truly asked myself before: (and that is) If productivity and results matter to us—and they do now more than ever—how exactly are we using our brain to make them happen? Most of us were never taught how to apply neuroscience to improve productivity, results, or well-being. About a decade ago, I became fascinated by the mind-brain-results connection—and how science can be applied to our everyday lives. That's why I've made it my mission to bring you the world's top experts—so together, we can explore the intersection of science and social-emotional learning. We'll break down complex ideas and turn them into practical strategies we can use every day for predictable, science-backed results. Episode 376: PART 2 Featuring Dr. John Ratey For today's Episode 376, we continue with PART 2 of our review with Dr. John Ratey, covering the first health staple that we know is scientifically proven to boost our physical and mental health: exercise.  We first met Dr. Ratey on Episode 116[i]  (back in March 2021) on his book “The Revolutionary New Science of Exercise and the Brain.” Dr. Ratey is also an Associate Clinical Professor of Psychiatry at Harvard Medical School and an internationally recognized expert in Neuropsychiatry. Dr. Ratey has published over 60 peer-reviewed articles and 11 books in 17 languages. You'll notice that around the time of the pandemic, in 2020, our interviews took a turn towards health and wellness, and to stay on track, I created a framework of our Top 5 Health Staples on Episode 87[ii], which eventually evolved into our Top 6 Health Staples.

Private equity investment in health care facilities has grown substantially in the past decade. There have been hundreds of such acquisitions of health care facilities in the past decade, including physician practices, nursing home facilities, and hospitals involving hundreds of billions of dollars.At its most basic, private equity investors take over a health care company with the intention of increasing its value and reselling it for a profit. Advantages of such a strategy can be more capital investment and management expertise. Downsides include the use of leveraged buyouts that could saddle the acquired company with high levels of debt. On this episode, we're joined by Dr. Zuri Song, an associate professor of health care policy and medicine at Harvard Medical School, and an expert on the financial incentives, public policies, and private sector investment in the health care system. Dr. Song explained what research has found in studying private equity acquisitions in health care. On average, he said, these investments raise real concerns about both patient outcomes and access to care.State legislatures are at the forefront of regulation in this area with much of the regulation focusing on increased transparency into these transactions. I talked with two state legislators to get their perspective: Senator Tyler Johnson, a Republican from Indiana who is also a physician, and Senator Cindy Friedman, a Democrat from Massachusetts. They each discussed the legislative action in their states and how they view private equity investment.ResourcesThe Evolving Landscape of State Health Care Transaction Laws, NCSL Health Costs, Coverage and Delivery Database, NCSL 

Dan Sullivan and Peter Diamandis dive into the evolving concept of longevity, reframing it as age reversal. They discuss the ground-breaking work of David Sinclair, a leading researcher at Harvard Medical School, and his contributions to epigenetic age reversal. The conversation highlights the public's perception of aging and longevity, emphasizing the desire for not just a longer life, but a healthier and more vibrant one. In this episode: The shift from longevity to age reversal is now a more immediate and measurable goal in health and wellness. AI and robotics is accelerating research and development in age-reversal therapies and diagnostics. Muscle strength, particularly leg strength, is a key indicator of longevity and overall health.

In this episode, I'm joined by Dr. Alexandra Fuss, Ph.D., Director of Behavioral Medicine in Inflammatory Bowel Diseases at Massachusetts General Hospital and Instructor in Psychiatry at Harvard Medical School. Alexandra previously served as Director of Behavioral Health in Digestive Diseases and Assistant Professor of Psychiatry at Yale, and is a National Scientific Advisor for the Crohn's & Colitis Foundation and Associate Editor of Crohn's & Colitis 360 Journal. Together, we unpack the topic of medical gaslighting and invalidation in gastrointestinal care, what it is, why patients with gut–brain disorders are particularly vulnerable, and how subtle or systemic factors can leave patients feeling dismissed. Alexandra also shares practical strategies clinicians can use to build trust, improve communication, and ensure patients feel genuinely heard and cared for. Whether you've ever felt your symptoms weren't taken seriously, or you're a clinician wanting to better support your patients, this episode offers insightful and actionable guidance you won't want to miss. Please enjoy my conversation with Dr. Alexandra Fuss.

Is it possible to deliver life-changing news—with compassion—without sacrificing precious time or the physician's own well-being? It's a burning question for healthcare professionals everywhere, and the impact of getting it right goes far beyond the exam room. Not only does compassionate communication ease patient anxiety and foster loyalty, but it also drives better outcomes, even in the face of a system that pressures doctors to prioritize speed and productivity (those infamous RVUs!). As the demands on clinicians mount, many struggle with “compassion fatigue,” and patients often experience rushed, impersonal conversations when they need empathy and understanding most. This episode offers a solution—and hope—for both sides of the stethoscope. You should listen to this episode because my guest, Dr. Rachel Hitt, delivers a masterclass in patient communication. As Chief of Breast Imaging at Tufts Medical Center and Medical Director of Patient Experience for Tufts Medicine Integrated Network, she brings more than 20 years of clinical expertise and a passion for improving the way difficult news is shared with patients. Dr. Hitt is not only a practicing clinician; she's a certified facilitator in healthcare communication and a certified patient experience professional, dedicating herself to coaching and elevating the next generation of physicians. Her insights are practical, inspiring, and applicable well beyond healthcare—for anyone who faces moments of tough conversations and wants to make those moments matter. Here are three powerful questions Rachel answers on the show: Why do so many healthcare professionals struggle with delivering difficult news compassionately—and how can they overcome barriers like exhaustion, lack of time, and institutional pressure? What is the ART model for patient communication, and how does it transform a monologue into a meaningful dialogue, even when sharing devastating diagnoses? How do small gestures—like a brief pause, gentle touch, or simply asking permission to enter—impact patient experience, loyalty, and even the bottom line for hospitals and health systems? Listen in and subscribe! Find this episode on Apple Podcasts and Spotify, and catch all future episodes on your favorite podcast platforms: Apple Podcasts Spotify (Available wherever you get your podcasts—just search for “Delighted Customers”!) Meet Dr. Rachel Hitt Dr. Rachel Hitt, MD, MPH, is the Chief of Breast Imaging at Tufts Medical Center and Medical Director of Patient Experience for the Tufts Medicine Integrated Network. With more than two decades of experience, she has touched thousands of lives, guiding patients and their families through some of their most vulnerable moments. Rachel graduated from Harvard Medical School and completed her residency in radiology and fellowship in breast imaging at Massachusetts General Hospital—two of the nation's most prestigious medical institutions. She also holds a Master's in Public Health from the University of Michigan and is a certified facilitator in healthcare communication through the Academy of Communication and Healthcare. Rachel is a Certified Patient Experience Professional (CPXP), and she's equally comfortable in academic medical centers and private practice settings. She has dedicated much of her career to teaching, coaching clinicians, and speaking at conferences about how medical professionals can improve the patient experience—“chunking and checking” information, meeting people where they are, and nurturing authentic, empathetic relationships. Connect with Rachel on LinkedIn. References and Show Notes Academy of Communication in Healthcare Dr. Steven Tresiak's “power of 40 seconds” research (Ted Talk) LinkedIn: Dr. Rachel Hitt Book reference: "All Business is Personal" by Dr. Joseph Michelli (from prior episodes) RVU (Relative Value Units) model in healthcare Techniques for improving patient loyalty and experience Thanks for listening—subscribe and share if you want more episodes just like this!

Varmt välkommen till ett nytt avsnitt av Idrott-och ledarskapspodden! I det här avsnittet får du möta Helena Stenberg. Helena är hälsoexpert, utbildare och grundare av Butterfly Wellness. Helena har över 20 års erfarenhet inom hälsa, träning och välmående och är särskilt inriktad på att hjälpa kvinnor i och runt klimakteriet att hitta balans, energi och livsglädje. Hon är självläkningsterapeut, hälsocoach och certifierad Pilatesinstruktör och hon jobbar även med Yogalates som är en härlig kombo mellan yoga och pilates och som kombinerar styrka, smidighet och närvaro – perfekt för kvinnor vars kroppar och hormoner förändras. I det här samtalet pratar vi om kvinnors hälsa genom livet, vad klimakteriet egentligen är, hur träning, återhämtning och mental balans påverkar både kroppen och sinnet – och varför stress och kortisol ofta är en bortglömd faktor bakom viktuppgång och trötthet i klimakteriet. Det blir ett inspirerande avsnitt fyllt av kunskap och på slutet går Jenny igenom flera tips och råd över hur du hanterar stress och hon delar också sin nya kunskap från Harvard Medical School om "The six pellars of Lifestyle Medicine". samt det viktigaste i varje del för att bygga upp ditt välmående från grunden. Mer om Helena Stenberg hittar du på www.butterflywellness.se och du kan följa henne på Instagram på @bluebutterflywellness. Och mer om vad som är på gång i Jenny's verksamhet hittar du på www.jennyhagman.com och bland annat finns det 4 platser kvar på hennes kommande Mentala träning och Yoga helg den 15-16/11. Läs mer och boka här: https://www.jennyhagman.com/mental-styrka-yoga-helg/ Ta hand om dig och varandra och den 1/11 kommer nästa avsnitt ut. Då är det dags för kapitel 7 i Jenny's bok Whole in one som handlar om Hjärtats kraft! Tack för att du lyssnar! Kram från Jenny och Team Train for Balance

In this thought-provoking episode, we delve into the profound impact of love and connection on our lives. The discussion centers around understanding emotions, developing an opportunity mindset, and building meaningful relationships. The conversation also touches on the importance of self-compassion and spiritual connections in navigating life's challenges.

This week we take a closer look at Retinopathy of Prematurity (ROP) -  from screening and staging to treatment and long-term outcomes. Join us as we shine some light on this sight-saving topic with insights from Dr. Nimesh Patel - Assistant Professor of Ophthalmology at Harvard Medical School and the director of Pediatric Vitreoretinal Surgery at Boston Children's Hospital. You won't believe your eyes at how much there is to see in the world of ROP care!

The FiltrateJoel Topf @kidneyboy.bsky.social‬Swapnil Hiremath @hswapnil.medsky.socialNayan Arora captainchloride.bsky.socialSopia Ambruso @sophia-kidney.bsky.socialSpecial Guests Brendon Neuen @brendonneuen.bsky.social Associate Professor and Program Lead, Renal and Metabolic at The George Institute for Global Health. Nephrologist and Director of Kidney Trials at Royal North Shore Hospital.Neuen has had three prior appearances on Freely Filtered: EMPA Kidney, DUPLEX and Sparsentan in FSGS, FLOW and SemaglutideMuthiah Vaduganathan @mvaduganathan on X. Cardiologist at Brigham and Women's Hospital and Harvard Medical School. Assistant Professor of Medicine.Editing byJoel TopfThe Kidney Connection written and performed by Tim YauShow NotesDONATE to NephJC! Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes NEJM | NephJC SummaryFIDELIO Bakris et al, NEJM 2020 | NephJC Summary; subgroup throws doubt on efficacy of finerenone in patients on flozinsFIGARO Pitt et al, NEJM 2021; subgroups clearly shows finerenone works, flozins or notNEJM editorial (wrongly) saying do not use Flozins unless on RASi Don't use dual RAS blockade ONTARGET Yusuf et al, NEJM 2008; VA NEPHRON-D Fried et al NEJM 2013Why we cannot study finerenone in HFrEF (RALES Pitt et al NEJM 1999) Muthu is jealous of GFR slope and albuminuria surrogate endpoints and wants to borrow them for HFpEF (Inker et al EHJ 2025)Combination therapy and CV outcomes in hypertension (Wang et al JAMA Card 2024 on low dose combinations and BP; Egan et al Blood Pressure 2022 review of topic) CONFIRMATION HF trial registry entry (Finerenone and Empagliflozin in hospitalized patients with HF)23:20: Nayan and Swap miss a chance to say ‘de-flozination' to discuss stopping a flozin which would allow a patient to be included in the trial Finerenone is a CYP3A4 substrate (Heinig et al Clin Pharmacokinetics 2023); Useful list of CYP3A4 inducers and inhibitors Everyone should get an ABPM (Bugeja et al CMAJ 2022)EASiKIDNEY study design Albuminuria mediates CKD benefits with Finerenone (Agarwal et al Ann Intern Med 2023)GFR slope and Albuminuria and the FDA (Taylor et al eClin Med 2025) Dapagliflozin and Eplerenone combination crossover trial (Provenzano et al JASN 2022)Joel gets promoted! (PBFluids reflection) Bluesky NephJC Chat discussion on ‘renal remission' Withdrawal of Finerenone and worse outcomes from FINEARTS (Vaduganathan et al JACC 2025)Combination therapies Analysis from Brendan and Muthu (Neuen et al Circulation 2024)Do not use KFRE when GFR > 60 (KDIGO Practice Point 2.2.4: Note that risk prediction equations developed for use in people with CKD G3–G5, may not be valid for use in those with CKD G1–G2) Finerenone vs Spironolactone trial in Primary Aldosteronism (Hu et al Circulation 2025)FIND CKD trial design (Heerspink et al NDT 2025) FINE-ONE trial design (Heerspink et al Diab Res Practice 2023) Tubular SecretionsNayan keeping his chin up as Yankees lose and Mariners follow (MLB Playoffs)Sophia's adventures with Beekeeping (Royal Jelly?) Brendon loves listening to ‘Susan' by Raye Muthu is back into Taekwondo Swap is still reading Martha Wells (Witch King on GoodReads)Joel will be hiking the Laugavegur trail in Iceland

Options for the treatment of acute myeloid leukemia (AML) are rapidly expanding, says Amir Fathi, MD, associate professor of medicine at Harvard Medical School in Boston and program director of the Center for Leukemia at Massachusetts General Hospital. “Over the course of the last 10 to 12 years, there have been a series of approvals, predominantly for targeted therapies,” he explains. Speaking with Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology, Dr. Fathi outlines how and when to look for mutations in AML and key considerations for various targeted therapies. He also shares what developments he is anticipating. “I'm most excited about where we're moving in the upfront setting.” Dr. Fathi reported various financial relationships. Dr. Figlin reported various financial relationships.

Season 14, episode 375 reviews episode 116 with Dr. John Ratey, exploring how exercise and lifestyle shape brain health and learning. The episode highlights Naperville's Zero Hour PE case study, explains how physical activity boosts attention and academic performance, and introduces BDNF (brain-derived neurotropic factor) as “miracle grow” for the brain. Practical takeaways include exercising before challenging work or school, prioritizing low-glucose nutrition, using hormesis (fasting, intense exercise, sauna) to increase resilience, and improving sleep and stress management to support cognitive health. On today's episode #375, we review our 2021 interview with Dr. John Ratey and will learn: ✔ How physical activity boosts attention and academic performance to improve results at school or in the workplace. ✔ What should we all understand about BDNF (brain-derived neurotropic factor) also known as “miracle grow” for the brain. ✔ How to build a faster, stronger, more resilient brain with exercise, nutrition, and with understanding hormesis. Welcome back to SEASON 14 of The Neuroscience Meets Social and Emotional Learning Podcast, where we connect the science-based evidence behind social and emotional learning and emotional intelligence training for improved well-being, achievement, productivity and results—using what I saw as the missing link (since we weren't taught this when we were growing up in school), the application of practical neuroscience. I'm Andrea Samadi, and seven years ago, launched this podcast with a question I had never truly asked myself before: (and that is) If productivity and results matter to us—and they do now more than ever—how exactly are we using our brain to make them happen? Most of us were never taught how to apply neuroscience to improve productivity, results, or well-being. About a decade ago, I became fascinated by the mind-brain-results connection—and how science can be applied to our everyday lives. That's why I've made it my mission to bring you the world's top experts—so together, we can explore the intersection of science and social-emotional learning. We'll break down complex ideas and turn them into practical strategies we can use every day for predictable, science-backed results. Episode 375: Featuring Dr. John Ratey For today's Episode 375, we continue with our review of past episodes as we make connections to prior learning with whatever it is that we are currently working on this year. I'll create a roadmap at the end of this season so this pathway will make sense to us (I hope!) as we piece together important parts of our success puzzle and begin to bring them to life. You'll notice that around the time of the pandemic, in 2020, our interviews took a turn towards health and wellness, and to stay on track, I created a framework of our Top 5 Health Staples on Episode 87[i], which eventually evolved into our Top 6 Health Staples. Today, we covering the first health staple of exercise, jumping to Episode 116[ii]  on “The Revolutionary New Science of Exercise and the Brain” with best-selling author Dr. John Ratey. Dr. Ratey is also an Associate Clinical Professor of Psychiatry at Harvard Medical School and an internationally recognized expert in Neuropsychiatry. Dr. Ratey has published over 60 peer-reviewed articles and 11 books in 17 languages, including the groundbreaking ADHD “Driven to Distraction” series with Dr. Edward (Ned) Hallowell, MD. With the publication of “Spark: The Revolutionary New Science of Exercise and the Brain,” Dr. Ratey established himself as one of the world's foremost authorities on the brain-fitness connection. His most recent book, “Go Wild,” explores how we can achieve optimal physical and mental health by getting in touch with our caveman roots and how we can “re-wild” our lives.

Get started with 1 month free of Superhuman today, using my link: https://try.sprh.mn/briankeating Today's guest made bacteria immune to every virus that exists. This breakthrough could revolutionize medicine by creating virus proof cell therapies and potentially extending this protection to human cells. Also demonstrating that we can fundamentally rewrite the language of life itself, something that was previously thought impossible. George Church is a Harvard Medical School genetics professor and pioneer of synthetic biology. He's an entrepreneur who's found in multiple biotech companies and is known for pushing the boundaries between science fiction and reality. His team just did something that sounds like pure science fiction. They made living cells completely immune to every virus on Earth. That resistant immune, every single virus that tries to infect your cells just fails. The viruses can't evolve around it. Here's the wild part. They didn't add anything new. They just removed a few letter from the genetic alphabet. But George isn't stopping there. He wants to do this to human cells. He's talking about engineering astronauts for Mars missions, bringing back wooly mammoths, and maybe even, just maybe, making humans virus proof to the implications are staggering. The ethics are murky. And the timeline. Well, if church's track record tells us anything is happening far faster than we think. KEY TAKEAWAYS 00:00:00 – Church's team made cells virus-proof, a major medical breakthrough 00:02:34 – Radiation resistance may come from DNA repair linked to desiccation 00:04:43 – A few genes can boost bacteria's radiation resistance 00:07:16 – Panspermia is unlikely due to harsh space conditions 00:10:50 – Space travel may need biological, not just physical, changes 00:14:19 – Regenesis explores synthetic biology's potential 00:18:19 – Height involves many genes, but single ones can have big effects 00:20:57 – Once sci-fi, genome sequencing and pig organs are now real 00:23:20 – Church and Venter are more collaborators than rivals 00:27:17 – Rewriting genes can create virus-proof organisms 00:35:36 – DNA can store data, but reading/writing is slow 00:41:06 – Gattaca and Jurassic Park portray genetics well with small flaws 00:44:03 – Gene therapies can be affordable for all 00:46:44 – Stem cells can create any body cell for therapy 00:49:15 – “Mirror humans” are possible but avoided ethically 00:53:59 – Genomic privacy isn't an issue since we shed DNA constantly 00:56:09 – Gene editing helps endangered species adapt, not revive extinct ones 01:00:30 – Virus-proof humans are possible, but tough to deliver to all cells 01:02:59 – Gene therapies could reverse aging at the cellular level 01:04:18 – Church avoids saying “impossible,” but admits to timeline optimism - Get My NEW Book: Focus Like a Nobel Prize Winner: https://www.amazon.com/dp/B0FN8DH6SX?ref_=pe_93986420_775043100 Please join my mailing list here

In this episode of The HemOnc Pulse, host Melissa speaks with Omar Nadeem, MD, Senior Physician at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, about emerging genomic insights in smoldering multiple myeloma. The discussion focuses on recent research showing how molecular profiling can improve understanding of disease progression and refine risk stratification beyond traditional clinical models. Dr. Nadeem highlights how genomic data may help distinguish patients with smoldering myeloma who are at higher risk of progression from those likely to remain stable, offering the potential to guide more personalized treatment decisions. The conversation also explores the evolving landscape of precursor plasma cell disorders and the role of immunotherapy, including CAR T-cell therapy, in clinical management.      

Join Dr. Cecilia Lansang, Associate Editor of Endocrine Practice, Professor of Medicine, and Director of Endocrinology at Cleveland Clinic, as she speaks with Dr. Kristen Flint, Interim Director of Quality and Safety for Endocrinology at Massachusetts General Hospital, Attending Endocrinologist at MGH, and Instructor at Harvard Medical School, about her team's quality improvement project, “Expanding Access to Continuous Glucose Monitoring in Medicare Patients Receiving Specialty Diabetes Care.” This episode covers:Strategies for implementing quality improvement interventions in a large academic diabetes specialty clinicKey interventions that increased CGM utilization, including targeted provider education, workflow optimization, and patient outreachLessons for advancing equitable implementation and sustaining quality improvement over time Tune in for practical insights on bridging policy changes and clinical practice to improve CGM access for Medicare patients. Read the full article in the August 2025 issue of Endocrine Practice here.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Sammons, MD About 40 percent of patients with metastatic HR+/HER2- breast cancer have an activating mutation in the PIK3CA gene,1,2 which plays a key role not only in tumor growth, but also in driving resistance to endocrine therapy.3-5 And while there are several FDA-approved PI3K pathway-targeted agents for patients with PIK3CA tumor mutations,6-8 they come with challenges, like modest efficacy and on-pathway effects.9-12 Given this unmet need, the ReDiscover trial evaluated the investigational agent RLY-2608 in combination with fulvestrant in in patients with PIK3CA-mutated HR+/HER2- aBC previously treated with a CDK4/6 inhibitor.13 Joining Dr. Charles Turck to share updated safety and efficacy data from the trial is Dr. Sarah Sammons, a Senior Physician at the Dana-Farber Cancer Institute and an Assistant Professor of Medicine at Harvard Medical School in Boston. References: Vasan N, Cantley LC, Vasan N, Cantley LC. At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy. Nat Rev Clin Oncol. 2022;19(7):471-485. doi:10.1038/s41571-022-00633-1 Network TCGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. doi:10.1038/nature11412 Saal LH, Johansson P, Holm K, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor …

Dr K is a psychiatrist, Harvard Medical School instructor, co-founder of Healthy GamerGG, Twitch streamer and a YouTuber. Why are we driven by what destroys us? Using anger or jealousy can spark our motivation, but when it goes too far, it consumes us. What are healthier ways to stay motivated, and how do we find peace instead of pressure Expect to learn why mean have become less dangerous and more useless, why toxic motivation is on the rise and how to not fall into it's trap, why incel violence is not a bad as it could be, how to structure your motivation so it's actually healthy, why so many men are obsessed with penis size, what women actually find attractive in a man, if having a dad-bod makes you a better dad, the dangers of bro science, why men cry at certain point in weddings and much more… Sponsors: See discounts for all the products I use and recommend: https://chriswillx.com/deals Get a Free Sample Pack of LMNT's most popular flavours with your first purchase at https://drinklmnt.com/modernwisdom Get 5 Free Travel Packs, Free Liquid Vitamin D, and more from AG1 at https://ag1.info/modernwisdom Get a 20% discount on Nomatic's amazing luggage at https://nomatic.com/modernwisdom Get 35% off your first subscription on the best supplements from Momentous at https://livemomentous.com/modernwisdom Timestamps: (0:00) Toxic Fuel Motivates Us (11:29) Why Men Go from Sad to Mad (22:24) Are Porn and Video Games Making Men Useless? (30:16) Why We Need Different Fuel at Different Stages (40:09) The Benefits of Beginning Again (50:04) Harnessing the Power of Meditation (01:04:18) Why We Should Stretch Ourselves (01:17:06) Does Muscle Mass Lead to Unsuccessful Relationships? (01:33:27) Why are Dad Bods Attractive? (01:39:17) Are Acts of Kindness Motivated by Toxic Fuel? (01:48:55) Sl*t-Shaming and Simp-Shaming are Mostly Intrasexual (01:59:21) Why We Use Boundaries as Protection (02:07:42) How Do Men and Women Differ in Relationships? (02:17:46) What Makes Grooms Cry? (02:22:36) ChatGPT Tells You What You Want to Hear (02:30:50) How to Find Your True Self (02:45:01) Chris' Journey With His Sense of Self (02:51:07) Where to Find Dr K Extra Stuff: Get my free reading list of 100 books to read before you die: https://chriswillx.com/books Try my productivity energy drink Neutonic: https://neutonic.com/modernwisdom Episodes You Might Enjoy: #577 - David Goggins - This Is How To Master Your Life: https://tinyurl.com/43hv6y59 #712 - Dr Jordan Peterson - How To Destroy Your Negative Beliefs: https://tinyurl.com/2rtz7avf #700 - Dr Andrew Huberman - The Secret Tools To Hack Your Brain: https://tinyurl.com/3ccn5vkp - Get In Touch: Instagram: https://www.instagram.com/chriswillx Twitter: https://www.twitter.com/chriswillx YouTube: https://www.youtube.com/modernwisdompodcast Email: https://chriswillx.com/contact - Learn more about your ad choices. Visit megaphone.fm/adchoices

What do you do when someone you love - whether it's your kids, a spouse, or a friend - keeps doing the same maddening things?  This week, we're tackling how to approach the most frustrating dynamics in any relationship. Dr. Alison is joined by award-winning psychologist Dr. J. Stuart Ablon, founder of Think:Kids at Massachusetts General Hospital, and Associate Professor at Harvard Medical School.  He shares a game-changing mindset shift: most challenging behavior is about skill, not will. If you've ever thought, “They just don't care,” about someone you love, this conversation provides a proven, practical path to real solutions.  This episode explores: The five core skills that drive every behavior The real reason most people struggle How to keep your cool and trade judgment for curiosity The exact words that lower defensiveness fast Why boundaries still matter—and how to set them collaboratively A step-by-step walkthrough of Collaborative Problem Solving in action For more from Dr. Stuart Ablon, check out his many free resources:

Sign up for my FREE webinar - Get Off the “Hot Girl” Hamster Wheel! Visit innerglowvitamins.com and use my code DRMINA for 10% off your order at checkout. You care for your face, your body, your mind, but when was the last time you cared for the skin down there? In this candid episode of The Skin Real, Dr. Mary Alice Mina sits down with urogynecologist Dr. Nabila Noor to talk about one of the most overlooked parts of women's wellness: vulvar skin. Together, they unpack the myths, shame, and silence surrounding “the skin where the sun doesn't shine,” reminding women that caring for this area isn't taboo, it's essential. Dr. Noor brings her expertise and empathy to every question, explaining how vulvar and vaginal skin differ, what products are safe (and which to skip), and why issues like irritation, dryness, and incontinence are common, but never normal. From postpartum recovery to perimenopause, this episode is a masterclass in reclaiming body literacy. It's an honest, empowering reminder that your body deserves care, curiosity, and compassion Key Takeaways: ✓ The vulva is external skin—distinct from the internal vagina, and requires gentle, fragrance-free care. ✓ “Less is more”: water is the best cleanser; avoid douching and scented wipes that disrupt your natural balance. ✓ Postpartum changes like dryness, laxity, or leakage are common and reversible with support and pelvic floor therapy. ✓ Estrogen loss in breastfeeding and menopause can cause dryness, discomfort, and incontinence, but these can be treated. ✓ Simple, safe moisturizers like petroleum jelly, coconut oil, or zinc-based creams often outperform marketed “feminine care” products. ✓ Shame and misinformation keep women silent—knowing your anatomy and seeking help early can prevent long-term issues. ✓ Women's health is whole-body health: caring for your vulva is an act of confidence, not vanity. This is the conversation we've all needed, but rarely had. Whether you're navigating postpartum healing, perimenopause, or simply curious about how to better care for yourself, this episode will leave you informed, affirmed, and empowered.  Dr. Nabila Noor is a nationally recognized Urogynecologist, Pelvic Reconstructive Surgeon, and Assistant Professor with advanced fellowship training from Harvard Medical School. As a double board-certified expert and high-volume surgeon, she is a thought leader in women's pelvic health, surgical innovation, and patient education. Through her global digital platforms, she empowers thousands of women to take charge of their pelvic and sexual health without shame. Follow Dr. Noor here: www.drnabilanoor.com https://www.instagram.com/drnabilanoor/ https://www.youtube.com/@drnabilanoor Want more expert skin advice without the overwhelm? Grab the R.E.A.L. Skin Method ebook for 50% off. Use Code REAL50 Subscribe to The Skin Real Podcast wherever you listen, and visit www.theskinreal.com for dermatologist-backed tips to help you feel confident in your skin—at every age. Follow Dr. Mina here:-  https://instagram.com/drminaskin https://www.facebook.com/drminaskin https://www.youtube.com/@drminaskin https://www.linkedin.com/in/drminaskin/ Visit Dr. Mina at Baucom & Mina Derm Surgery Website: atlantadermsurgery.com Email: scheduling@atlantadermsurgery.com Call: (404) 844-0496 Instagram: @baucomminamd Thanks for tuning in. And remember—real skin care is real simple when you know who to trust. Disclaimer: This podcast is for entertainment, educational, and informational purposes only and does not constitute medical advice.

In this episode of Growing Older Living Younger, Dr. Gillian Lockitch speaks with Dr. Bruce Gillis about chronic immune system disorders such as fibromyalgia, chronic fatigue syndrome, interstitial cystitis, and long COVID. Dr. Gillis shares how his research overturned decades of stigma by proving these conditions are objectively measurable through immune system testing and DNA genomic signatures. The conversation explores the role of epigenetics in disease development, the link between coronaviruses and long COVID, and the discovery of a microbiome-modulating compound that reduces symptoms. Listeners will gain validation, clarity, and practical insights into how accurate diagnosis and targeted therapies can improve quality of life. Dr. Bruce Gillis is a physician-scientist and public health expert whose career spans clinical medicine, research, and academic leadership. After earning his MD from the University of Illinois College of Medicine and his MPH from the Harvard School of Public Health, he completed two residencies and two fellowships before joining the faculty at Harvard Medical School, UCLA, and the University of Illinois. His early work focused on environmental health and toxic exposures, including oversight of the Alaskan oil spill cleanup and aerospace medicine projects. Dr. Gillis later turned his focus to chronic immune system disorders such as fibromyalgia, chronic fatigue syndrome, interstitial cystitis, and long COVID. Through groundbreaking research, his team identified specific white blood cell dysfunctions and unique DNA genomic signatures that objectively prove fibromyalgia and related disorders are real, diagnosable conditions. He pioneered the development of the FibroTest, an FDA-reviewed diagnostic blood test now covered by Medicare and many insurers, and continues to study therapeutic compounds that support microbiome health and improve symptom management.   Episode Timeline  00:00 – Welcome & Introduction Podcast focus on aging youthfully; Gillian introduces Dr. Gillis and chronic immune disorders.  05:51 – Dr. Gillis' Journey From rural upbringing to Harvard MD/MPH; work in environmental health, aerospace, and proving fibromyalgia is real.  08:44 – What Are Chronic Immune Disorders? Definitions, stigma, and why current drugs only mask symptoms.  12:17 – Epigenetics & Long COVID How environmental triggers and coronaviruses drive epigenetic DNA changes linked to fibromyalgia and chronic fatigue.  16:40 – Blood-Based Diagnostics Immune system testing, identification of protein deficiencies, and discovery of unique DNA genomic signatures.  18:56 – Comparing Conditions How fibromyalgia, chronic fatigue, and interstitial cystitis differ yet share immune dysfunction.  25:34 – Better Diagnostics for Interstitial Cystitis Blood tests prove 11x more accurate than invasive cystoscopy.  27:15 – Therapies & Lifestyle Nutrition, hydration, and discovery of the mycobacterium-derived compound Imbics that supports microbiome health.  34:40 – Future Directions Expanding research into long COVID and other chronic conditions; improving management, not curing DNA changes.  Download your gifts: Mind and Memory Boosting Strategies Connect with Dr. Gillian Lockitch Email: askdrgill@gmail.com Subscribe to Growing Older Living Younger on your favorite podcast platform and leave a review to help others discover the show. Share this episode with friends  Learn about Dr. Gillis's work here: www.thefibrotest.com www.imbxx.com www. the1test.com

If you're enjoying the content, please like, subscribe, and comment! Dr. Schwartz's Links: Website: https://www.theodorehschwartzmd.com/ Book: https://www.penguinrandomhouse.com/books/734286/gray-matters-by-theodore-h-schwartz/ Theodore H. Schwartz, MD graduated Magna Cum Laude in Philosophy and English from Harvard University and Magna Cum Laude in Neuroscience from Harvard Medical School. After completing his residency and chief residency in Neurosurgery at The Neurological Institute of New York at Columbia-Presbyterian Medical Center, Dr. Schwartz spent a year at Yale-New Haven Medical Center where he received advanced fellowship training in epilepsy and brain tumor surgery. He completed a post-doctoral fellowship at the Max Planck Institute in Munich, Germany funded by the Van Wagenen Fellowship and the Von Humboldt Society. Dr. Schwartz spent 25 years as a Professor of Neurosurgery, Otolaryngology, and Neuroscience at Weill Cornell Medical College, New York Presbyterian Hospital. He was named David and Ursel Barnes Professor in Minimally Invasive Surgery, the first endowed professorship in the department, Vice-Chairman of Clinical Research, the Director of Anterior Skull Base and Pituitary Surgery, Co-Director of Surgical Neuro-Oncology, the Director of Epilepsy Surgery, and ran a basic science laboratory investigating the causes and treatment for epilepsy. He has received K08, R01 and R21 funding from the NINDS for his research and has served on several NIH review committees.Dr. Schwartz's book Gray Matters: A Biography of Brain Surgery, published by Dutton/Penguin-Random House, was selected by The Economist as one of the best books of 2024. His nonfiction writing has been featured in the Wall Steet Journal, the Boston Globe, Psyche Magazine, and The Psychologist. Dr. Schwartz is currently the Founder and CEO of a med tech device company called illumination Diagnostics._______________________Follow us!@worldxppodcast Instagram - https://bit.ly/3eoBwyr@worldxppodcast Twitter - https://bit.ly/2Oa7BzmSpotify - http://spoti.fi/3sZAUTGYouTube - http://bit.ly/3rxDvUL#neuroscience #surgeon #medschool #medical #neurosurgeon #surgery #medicine #medicalstudent #cte #tbi #trauma #traumaticbraininjury #concussion #subscribe #explore #explorepage #podcastshow #longformpodcast #podcasts #podcaster #podcasting #worldxppodcast #viralvideo #youtubeshorts

JCO PO author Dr. Asaf Maoz at Dana-Farber Cancer Institute shares insights into article, “Causes of Death Among Individuals with Lynch Syndrome in the Immunotherapy Era.” Host Dr. Rafeh Naqash and Dr. Maoz discuss the causes of death in individuals with LS and the evolving role of immunotherapy. TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCOPO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor Medicine, at the OU Health Stephenson Cancer Center. Today, I'm super thrilled to be joined by Dr. Asaf Maoz, Medical Oncologist at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and faculty at the Harvard Medical School, and also lead author on the JCO Precision Oncology article entitled "Causes of Death Among Individuals with Lynch Syndrome in the Immunotherapy Era." This publication will be a concurrent publication with an oral presentation at the annual CGA meeting. At the time of this recording, our guest's disclosures will be linked in the transcript. Asaf, I'm excited to welcome you on this podcast. Thank you for joining us today. Dr. Asaf Maoz: Thank you so much for highlighting our paper. Dr. Rafeh Naqash: Absolutely. And I was just talking to you that we met several years back when you were a trainee, and it looks like you've worked a lot in this field now, and it's very exciting to see that you consider JCOPO as a relevant home for some of your work. And the topic that you have published on is of significant interest to trainees from a precision medicine standpoint, to oncologists in general, covers a lot of aspects of immunotherapy. So, I'm really excited to talk to you about all of this. Dr. Asaf Maoz: Me too, me too. And yeah, I think JCOPO has great content in the area of cancer genetics and has done a lot to disseminate the knowledge in that area. Dr. Rafeh Naqash: Wonderful. So, let's get started and start off, given that we have hosts of different kinds of individuals who listen to this podcast, especially when driving from home to work or back, for the sake of making everything simple, can we start by asking you what is Lynch syndrome? How is it diagnosed? What are some of the main things to consider when you're trying to talk an individual where you suspect Lynch syndrome? Dr. Asaf Maoz: Lynch syndrome is an inherited predisposition to cancer, and it is common. So, we used to think that, or there's a general notion in the medical community that it is a rare condition, but we actually know now from multiple studies, including studies that look at the general population and do genetic testing regardless of any clinical phenotype, that Lynch syndrome is found in about 1 in 300 people in the general population. If you think about it in the United States, that means that there are over a million people living with Lynch syndrome in the United States. Unfortunately, most individuals with Lynch syndrome don't know they have Lynch syndrome at the current time, and that's where a lot of the efforts in the community are being made to help detect more individuals who have Lynch syndrome. Lynch syndrome is caused by pathogenic germline variants in mismatch repair genes, MLH1, MSH2, MSH6, or PMS2, or as a result of pathogenic variants in EPCAM that cause silencing of the MSH2 gene. Dr. Rafeh Naqash: Excellent. Thank you for that explanation. Now, one of the other things I also realized, similar to BRCA germline mutations, where you require a second hit for individuals with Lynch syndrome to have mismatch repair deficient cancers, you also require a second hit to have that second hit result in an MSI-high cancer. Could you help us understand the difference of these two concepts where generally Lynch syndrome is thought of to be cancers that are mismatch repair deficient, but that's not necessarily true for all cases as we see in your paper. Can you tease this out for us a little bit more? Dr. Asaf Maoz: Of course, of course. So, the germline defect is in one of the mismatch repair genes, and these genes are responsible for DNA mismatch repair, as their name implies. Now, in a normal cell, we think that one working copy is generally enough to maintain the mismatch repair machinery intact. What happens in tumors, as you alluded to, is that there is a second hit in the same mismatch repair gene that has the pathogenic germline variant, and that causes the mismatch repair machinery not to work anymore. And so what happens is that there is formation of mutations in the cancer cell that are not present in other cells in the body. And we know that there are specific types of mutations that are associated with defects in mismatch repair mechanisms, and those are associated a lot of times with frameshift mutations. And we have termed them ‘microsatellites'. So there are areas in the genome that have repeats, for example, you know, if you have AAAA or GAGA, and those areas are particularly susceptible to mutations when the mismatch repair machinery is not working. And so we can measure that with DNA microsatellite instability testing. But we can also get a sense of whether the mismatch repair machinery is functioning by looking at protein expression on the surface of cancer cells and by doing immunohistochemistry. More recently, we're also able to infer whether the mismatch repair machinery is working by doing next-generation sequencing and looking at many, many microsatellites and whether they have this DNA instability in the microsatellites. Dr. Rafeh Naqash: Excellent explanation. As a segue to what you just mentioned, and this reminds me of some work that one of my good friends, collaborators, Amin Nassar, whom you also know, I believe, had done a year and a half back, was published in Cancer Cell as a brief report, I believe, where the concept was that when you look at these mismatch repair deficient cancers, there is a difference between NGS testing, IHC testing, and maybe to some extent, PCR testing, where you can have discordances. Have you seen that in your clinical experience? What are some of your thoughts there? And if a trainee were to ask, what would be the gold standard to test individuals where you suspect mismatch repair deficient-related Lynch syndrome cancers? How would you test those individuals? Dr. Asaf Maoz: We do sometimes see discordance, you know, from large series, the concordance rate is very high, and in most series it's over 95%. And so from a practical perspective, if we're thinking about the recommendation to screen all colorectal cancer and all endometrial cancer for mismatch repair deficiency, I think either PCR-based testing or immunohistochemistry is acceptable because the concordance rate is very high. There are rare cases where it is not concordant, doing multiple of the tests makes sense at that time. If you think about the difference between the tests, the immunohistochemistry looks at protein expression, which is a surrogate for whether there is mismatch repair deficiency or not, right? Because ultimately, the mismatch repair deficiency is manifested in the mutations. So if the PCR does not show microsatellite instability and now NGS does not show microsatellite instability, the IHC may be a false positive. At the end of the day, the functional analysis of whether there are actually unstable microsatellites either by PCR or by NGS is what I would consider more informative. But IHC again is an excellent test and concordant with those results in over 95% of cases. Now there is also an issue of sampling. It's possible that there's heterogeneity within the tumor. We published a case in JCOPO about heterogeneity of the mismatch repair status, and that was both by immunohistochemistry, but also by PCR. So there are some caveats and interpreting these tests does require some expertise, and I'm always happy to chat with trainees or whoever has an interesting or challenging case. Dr. Rafeh Naqash: Thanks again for that very easy to understand explanation. Now going to management strategies, could you elaborate a little bit upon the neo-adjuvant data currently, or the metastatic data which I think more people are familiar with for immunotherapy in individuals with MSI-high cancers? Dr. Asaf Maoz: Yeah, that's an excellent question and obviously a very broad topic. Individuals with Lynch syndrome typically develop tumors that are mismatch repair deficient or microsatellite unstable. And we have seen over the last 15 years or so that these tumors, because they have a lot of mutations and because these mutations are very immunogenic, we have seen that they respond very well to immunotherapy. And this has been shown across disease sites and has been shown across disease settings. And for that reason, immunotherapy was approved for MSI-high or mismatch repair deficient cancer regardless of the anatomic site. It was the first tissue-agnostic approval by the FDA in 2017. And so there are exciting studies both in the metastatic setting where we see individuals who respond to immunotherapy for many years, and one could wonder whether their cancer is going to come back or not. And also in the earlier setting, for example, the Cercek et al. study in the New England Journal from Sloan Kettering, where they showed that neoadjuvant immunotherapy can cause durable responses for rectal cancer that is mismatch repair deficient. And in that series, the patients did not require surgery or radiation, which is standard of care for rectal cancer otherwise. And there's also exciting data in the adjuvant space, as was presented in ASCO by Dr. Sinicrope, the ATOMIC study, and many more efforts to bring immunotherapy into the treatment landscape for individuals with MSI-high cancer, including individuals with Lynch syndrome. Dr. Rafeh Naqash: A lot of activity, especially in the neo-adjuvant and adjuvant space over the last two years or so. Now going to the actual reason why we are here is your study. Could you tell us why you looked at this idea of patients who had Lynch syndrome and died, and the reasons for their death? What was the thought that triggered this project? Dr. Asaf Maoz: As we were talking about, we now know that immunotherapy really has changed the treatment landscape for individuals with Lynch syndrome, and that most cancers that individuals with Lynch syndrome do have this mismatch repair deficiency. But we also know that individuals with Lynch syndrome can develop tumors that do not have mismatch repair deficiency, and we call them mismatch repair proficient or microsatellite stable. And there was a series from Memorial Sloan Kettering showing that in colorectal cancer, about 10% of the tumors that individuals with Lynch syndrome developed did not have mismatch repair deficiency. In addition to that, we anecdotally saw that some of our patients with Lynch syndrome died of causes that were not mismatch repair deficient tumors. We wanted to see how that has changed since immunotherapy was approved in a tissue-agnostic manner, meaning that we could look at this regardless of where the cancer started, because we would anticipate that if the tumor was mismatch repair deficient, the patient would be able to access immunotherapy as standard of care. Dr. Rafeh Naqash: Thank you. And then you looked at different aspects of correlations with regards to individuals that had an MSI-high cancer with Lynch syndrome or an MSS cancer with Lynch syndrome. Could you elaborate on some of the important findings that you identified as well as some of the unusual findings that perhaps we did not know about, even though the sample size is limited, but what were some of the unique things that you did identify through this project? Dr. Asaf Maoz: The first question was what cause is leading to death in individuals with Lynch syndrome? And we had 54 patients that we identified that had died since the approval of immunotherapy in 2017, 44 of which died of cancer-related causes. And when we looked at cancer-related causes of death, we wanted to know how many of those were due to mismatch repair deficient tumors versus mismatch repair proficient tumors or MS-stable tumors. And we found, somewhat surprisingly, that 43% of patients in our cohort actually died of tumors that were microsatellite stable or mismatch repair proficient, meaning of tumors that are not typically associated with Lynch syndrome. This is not entirely surprising as a cause of death because we know that immunotherapy does not typically work for tumors that are microsatellite stable. And so in the metastatic setting, there are much less cases of durable remissions with treatment. But it was helpful to have that figure as an important benchmark. There are previous studies about causes of death in Lynch syndrome, and particularly from the Prospective Lynch Syndrome Database in Europe. Those have provided really important information about cause of death by cancer site, but they typically don't have mismatch repair status and are more difficult to interpret in that regard. They also don't include a large number of individuals who have PMS2 Lynch syndrome, which is the most common, but least penetrant form of Lynch syndrome. Dr. Rafeh Naqash: As far as the subtype of pathogenic germline variants is concerned, did you notice anything unusual? And I've always had this question, and you may know more about this data, is: In the bigger context of immunotherapy, does the type of the pathogenic germline variant for Lynch syndrome associated MSI-high cancers, does that impact or have an association with the kind of outcomes, how soon a cancer progresses or how many exceptional responders perhaps with MSI-high cancers actually have a certain specific pathogenic germline variant? Dr. Asaf Maoz: That's an excellent question, and certainly we need more data in that space. We know that the type of germline mutation, or the gene in which there is a germline pathogenic variant, determines to a large degree the cancer risk, right? So we know that individuals who have germline pathogenic variants in MLH1 or MSH2 have a much higher colorectal cancer risk than, for example, PMS2. We know that for PMS2, the risks are more limited to colorectal and endometrial, and may be lower risk of other cancers. We also know that, you know, the spectrum of disease may change based on the pathogenic germline variants. For example, individuals who have MSH2 associated Lynch syndrome have more risk of additional cancers in other organs like the urinary tract and other less common Lynch-associated tumors. The question about response to therapy is one where we have much less information. There are studies that are trying to assess this, but I don't think the answer is there yet. Some of the non-clinical data looks at how many mutations there are based on the pathogenic variant and what the nature of those mutations are, whether they're more frameshift or others. But I think we still need more clinical data to understand whether the response to immunotherapy differs. It's also complicated by the fact that the immunotherapy landscape is changing, especially in the metastatic setting, now with the approval of combination ipilimumab and nivolumab for first-line treatment of colorectal cancer that is microsatellite unstable. But in our study, we did find that, as you would expect, there is an enrichment in MS-stable cancers among those with PMS2 Lynch syndrome. Again, our denominator is those who died, right? So this is not the best way to look at the question whether this is overall true, that is more addressed by the study that Sloan Kettering published. But we do see, as we would anticipate, that there are more microsatellite stable cancers among those with PMS2 Lynch syndrome that died. Dr. Rafeh Naqash: A lot to uncover there for sure. This study and perhaps some of the other work that you're doing is slowly advancing our understanding of some of these concepts. So I'd like to shift gears to a couple of provocative questions that I generally like to ask. The first is, in your opinion, and you may or may not have data to back this up, which is okay, and that's why we're having a conversation about it. In your opinion, do you think the type or the quality of the neoantigen is different based on the pathogenic germline variant and a Lynch syndrome associated MSI-high cancer? Dr. Asaf Maoz: I think there are some data out there that, you know, I can't cite off the top of my mind, but there are some data out there that suggest that that may be the case. I think the key question is the quality, right? I think that whether these differences that are found on a molecular level also translate to a clinical difference in response is something that is unknown at this moment. Some people hypothesize that if the tumor has less neoantigens, there's less of a response to immunotherapy. But I think we really need to be careful before making those assertions on a clinical level. I do think it's a really important question that needs to be answered, among others because, you know, in the colorectal space, for example, where we have both the option of doing ipilimumab with nivolumab and the option of doing pembrolizumab, we don't really know which patients need the CTLA-4 blockade versus which patients can receive PD-1 blockade alone and avoid the potential excess toxicity of the CTLA-4 blockade. There are a lot of interesting questions there that still need to be answered. And of course, individuals with Lynch syndrome are just a fraction of those individuals who have MSI-high cancer. So there's also the question about whether non-Lynch syndrome associated MSI-high cancer responds differently to immunotherapy than Lynch syndrome associated MSI-high cancer. A lot of very interesting questions in the field for sure. Dr. Rafeh Naqash: Absolutely. My second question is more about trying to understand the role of ctDNA, MRD monitoring in individuals with Lynch syndrome. If somebody has a germline, you know, Lynch syndrome MSI-high cancer, when you do a tumor-informed ctDNA assessment, what do you capture generally there? Because, and this question stems from a discussion I've had with somebody regarding EGFR lung cancer, since I treat individuals with lung cancer, and the concept generally is that even if the tissue showed EGFR, but for MRD monitoring, when you do a barcoded sequence of different tumor specific mutations, it's not actually the EGFR that they track in the blood when they do ctDNA assessment. But from a Lynch syndrome standpoint, if you have a germline, right, which is the first hit, and then you have the somatic in the tumor, which is the second hit, are you aware or have you tried to look into this where what is exactly being followed if one had to follow MRD in a Lynch syndrome MSI-high colorectal cancer? Dr. Asaf Maoz: I think a lot of the MRD assays are proprietary, and so we don't receive information about what the mutations that are being tracked are. In general, the idea is to track mutations that we would not expect to disappear as part of resistant mechanisms. We want these to be truncal mutations. We want these to be mutations in which resistance is not expected to result in reversion mutations. But what specifically is being tracked is something that I don't know because these assays, the tumor-informed ones, are proprietary, and we don't get the results regarding specific mutations. When it's circulating tumor DNA that is not necessarily tumor-informed, we do get those results, but that is less so about the specific selection of mutations. Dr. Rafeh Naqash: Thank you for clarifying that question to some extent, of course, as you said, we don't know a lot, and we don't know what we don't know. That's the most important thing that I've learned in the process of understanding precision medicine and genomics, and it's a very fast-paced evolving field. Last question related to your project, what is the next step? Are you planning any next steps as a bigger multicenter study or validation of some sort? Dr. Asaf Maoz: There are two big questions that this study raises. One, is this true across multiple other sites, right? Because this is a single center study, and we really need additional centers to look at their data and validate whether they are also seeing that a substantial portion of deaths in individuals with Lynch syndrome are attributable to mismatch repair proficient cancer. The other question is whether we can look at specifically MSI-high cancer versus MS-stable cancer and understand what the mortality rate for each of those are. From a clinical perspective, it's important to counsel individuals with Lynch syndrome about general cancer screening outside of mismatch repair deficient tumors and to understand that there is also a risk of mismatch repair proficient tumors and that treatment for those tumors would be different. There's a lot of work to be done in the future. Another major area of need is to see whether tumors that are microsatellite stable can be sensitized to immunotherapy, and that is beyond the Lynch syndrome field, but that is something that certainly would benefit these individuals with Lynch syndrome who develop mismatch repair proficient cancer. Dr. Rafeh Naqash: That's very interesting to hear, and we'll look forward to seeing some of those developments shape in the next few years. Now, I'd like to spend a minute, minute and a half on you specifically as a researcher, clinician, scientist. Could you briefly highlight - because I remember meeting you several years back as a trainee, with your interest in genomics, computational research - could you briefly tell us what led you to hereditary cancer syndromes based on your research and work? What are some of the things that you learned along the way that other early career investigators can perhaps take lessons from? Dr. Asaf Maoz: Big questions there, thanks for asking. I got interested in the field of hereditary cancer syndromes when I came to the United States and started doing lab research in Stephen Gruber's lab at the time at USC. He's now at City of Hope. And my interest was originally looking at immunotherapy and immunology, but I went to the case conferences where we were learning about individuals with hereditary cancer, and those were kind of earlier days where we were still trying to figure out how to test and what the implications for these individuals would be. And through fellowship, I was also very interested in that, and I did my senior fellowship years with Dr. Yurgelun here at Dana-Farber, who is the director of the Lynch Syndrome Center. And I I think it's the combination between being able to treat individuals based on precision medicine and what the germline mutation is, but also the ability to prevent cancer and to develop strategies to intercept cancer early that is really appealing to me in this field. It's also a great field to be in because it's a small field. If you come to the CGA-IGC meeting, you'll be able to interact with everyone. Everyone is super collaborative, super nice, and I really recommend it to trainees. The CGA-IGC annual meeting is really a great opportunity to learn more and experience some of the advancement specifically in the GI hereditary space. Lessons for trainees. I think there are a lot of lessons that I could think about, but I think finding strong and supportive mentors is one of the things that has helped me most. I think that just having close relationship with your mentor, having frequent discussions and honest discussions about what is feasible, what is going to make a difference for your patients and your research and what you want to focus on is really important. And so I think if I had to choose one thing, I would say choose a mentor that you trust, that you feel you have a good relationship with, and that has the availability to support you. Dr. Rafeh Naqash: Thank you so much for those insightful comments, and thank you for sharing with us your journey, your project, and some of your interesting thoughts on this concept of hereditary cancers. Hopefully, we'll see more of this work being published in JCOPO through your lab or work from others. Dr. Asaf Maoz: Thank you so much. I appreciate the opportunity to be here. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at ASCO.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Through its new partnership with Harvard Medical School, Microsoft is leaning on healthcare for its artificial-intelligence chatbot, Copilot, to gain independence from OpenAI's ChatGPT. WSJ reporter Sebastian Herrera shares exclusive details on that effort. Plus, AI is transforming how companies manage risk. Executives from FedEx and DBS Bank spoke at the recent Journal House Singapore event about how they are leveraging AI to navigate legal and regulatory challenges. Julie Chang hosts. Sign up for the WSJ's free Technology newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this special episode of Talking Sleep, host Dr. Seema Khosla offers an exclusive preview of the upcoming SleepMedicine Disruptors course, taking place November 14-15 in Austin, Texas. She speaks with Steve Van Hout, executive director of the AASM, and Dr. David White, professor of medicine part time at Harvard Medical School, about the groundbreaking innovations reshaping sleep medicine. Steve Van Hout explains what makes the Disruptors conference unique compared to other AASM meetings like Trends and the annual SLEEP conference. Designed to bring together clinicians, researchers, technology innovators,and venture capitalists, Disruptors aims to foster cross-industry collaboration and encourage investment in sleep medicine innovations. The conference features innovation award presentations similar to Shark Tank pitches with the audience voting on their favorites, keynote speakers, and discussions about emerging technologies that promise to transform how we diagnose and treat sleep disorders. Dr. White provides an in-depth preview of his presentation on pharmacotherapy for obstructive sleep apnea, sharing exciting developments in multiple drug candidates. He discusses Apnimed's AD-109, a combination of atomoxetine and R-oxybutynin, which has completed two phase three studies showing approximately 50% reduction in AHI across six-month and one-year trials involving over 650 patients each. With FDA submission planned for early 2026, this medication could reach the market by late 2026. The conversation explores other promising agents including Incannex's combination of dronabinol and acetazolamide, carbonic anhydrase inhibitors like sulthiame (recently licensed by Apnimed), and innovative potassium channelantagonists that could be delivered via nasal spray for localized upper airway effects with minimal systemic absorption. Dr. White discusses the potential for poly therapy approaches, combining medications with devices like mandibular advancement devices or positional therapy, drawing parallels to how hypertension and diabetes are managed with multiple treatments. The episode tackles important questions about the future of sleep medicine: Will pharmacotherapy replace PAP therapy, or will hybrid approaches become standard? What AHI reduction is clinically meaningful for cardiovascularprotection and symptom improvement? How will pricing and insurance coverage affect accessibility? They emphasize that while these medications may not replace CPAP entirely, they offer promising options for patients who struggle with existing therapies. Whether you're a sleep medicine practitioner interested in emerging treatments, an entrepreneur exploring innovation opportunities, or simply curious about the future of sleep disorder management, this episode provides essential insights into the rapidly evolving landscape of sleep medicine. Join us for this forward-looking conversation about innovation, investment, and the technologies poised to disrupt traditional sleep medicine practice.

Send us a textDr. David Joseph rejoins Dr. Michael Koren for part 2 of his journey from reluctant med student to medical consultant, inventor, and artist. In this section, Dr. Joseph talks about the difficulties in navigating our current, disjointed, and often impersonal medical system. He recounts having to go through seven different consultations with physicians before anyone physically examined him and how persistence is key in our medical system. They finish up by talking about the doctor's artwork, which can be found at https://www.davidjosephart.com/ and on Instagram at @artbydavidjosephBe a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Dr. Jeffrey Hull, a highly sought-after facilitator, keynote speaker, bestselling author, and executive coach to leaders across the globe, joins me on the latest Business Minds Coffee Chat. Jeff brings years of translating science into leadership as a consultant, psychologist, and teacher at New York University and Harvard Medical School. His work has been featured in Harvard Business Review, Investor's Business Daily, and other major media outlets.

Most of us think of medicine as something that comes in a pill bottle or a hospital setting. But what if one of the most powerful prescriptions for lowering blood pressure, calming anxiety, and even boosting immunity doesn't come from a pharmacy at all? What if it comes from the forest and elements of nature? Spending intentional time in nature doesn't just feel good; it rewires the nervous system, lowers stress hormones like cortisol, and even enhances immune defenses against disease.  Forest therapy taps into this ancient truth with modern scientific validation: our bodies, minds, and spirits were designed to thrive in connection with the natural world. Yet in our overstimulated, urbanized lives, that connection is fraying. We scroll endlessly, jump from task to task, and fill every quiet moment with noise.  Nature isn't just a backdrop for relaxation; it's an active participant in our healing.  Even a short walk among greenery reduces inflammation markers linked to chronic disease.  How do we tap into nature's healing abilities? How do we use forest therapy to quiet our inner chatter?  In this episode, I'm joined by healthcare leader, educator, certified executive coach, and certified Forest Therapy guide, Dr. Susan Abookire.  We explore the physiological, emotional, mental, and spiritual power of reconnecting with nature, and how to make it a habit.  We also talk about overlooked yet transformative interventions for stress, chronic disease, and emotional well-being.    Things You'll Learn In This Episode  -Stress isn't the root problem; disconnection is Chronic stress hormones drive disease, but is our real issue a loss of connection to nature and each other? -Why trees boost immunity What happens in your body when you inhale phytoncides, the compounds released by trees? How do they supercharge natural killer cells that fight infection and even cancer? -The attention restoration effect How does stepping into green space rebuild cognitive resources drained by digital overload and constant problem-solving? -The healing power of stillness From “sit spots” to slowing down your senses, how can simple daily practices in nature recalibrate your nervous system and deepen resilience?   Guest Bio Dr. Susan Abookire is a healthcare leader, educator, certified executive coach, and certified Forest Therapy guide. She started her career as an electrical engineer, designing aviation systems for aviation safety. Her journey then took her to Harvard Medical School, where she entered healthcare with a deep passion for designing healthy, thriving systems in healthcare delivery. After over 20+ years as a healthcare executive designing healthcare delivery systems, Dr. Abookire began teaching systems and relying on nature as our model and teacher. One day, she saw an article about Forest Bathing and becoming a Certified Forest Therapy Guide. I immediately connected with the knowledge that I was going to do this. One year later, in 2020, she began incorporating Forest Bathing and Forest Therapy in all her work. Dr. Abookire has dedicated her life to connecting us with ourselves, with nature, and with each other. Her programs include 1:1 coaching for women physician leaders, group coaching programs, and Nature as Medicine Practitioner training and certification. To learn more about Dr. Abookire's program, visit https://www.naturesystemsinstitute.com/.  About Your Host Hosted by Dr. Deepa Grandon, MD, MBA, a triple board-certified physician with over 23 years of experience working as a Physician Consultant for influential organizations worldwide. Dr. Grandon is the founder of Transformational Life Consulting (TLC) and an outspoken faith-based leader in evidence-based lifestyle medicine.   Resources Feeling stuck and want guidance on how to transform your spiritual, mental and physical well being? Get access to Dr Deepa's 6 Pillars of Health video! Visit drdeepa-tlc.org to subscribe and watch the video for free. ‌ Work with Me Ready to explore a personalized wellness journey with Dr. Deepa? Visit drdeepa-tlc.org and click on “Work with Me” to schedule a free intake call. Together, we'll see if this exclusive program aligns with your needs!  Want to receive a devotional every week From Dr. Deepa? Devotionals are dedicated to providing you with a moment of reflection, inspiration, and spiritual growth each week, delivered right to your inbox. Visit https://www.drdeepa-tlc.org/devotional-opt-in to subscribe for free. Ready to deepen your understanding of trauma and kick start your healing journey? Explore a range of online and onsite courses designed to equip you with practical and affordable tools. From counselors, ministry leaders, and educators to couples, parents and individuals seeking help for themselves, there's a powerful course for everyone. Browse all the courses now to start your journey.   ​​TLC is presenting this podcast as a form of information sharing only. It is not medical advice or intended to replace the judgment of a licensed physician. TLC is not responsible for any claims related to procedures, professionals, products, or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services, or methods that might be referenced. Check out this episode on our website, Apple Podcasts, or Spotify, and don't forget to leave a review if you like what you heard. Your review feeds the algorithm so our show reaches more people. Thank you!  

On this episode of SurgOnc today, Dr. Rosalinda Alvarado and Dr. George Molina moderate a discussion on how to improve the recruitment of Hispanic/Latino patients into clinical trials. Joining the conversation are Jeanette Gonzalez from the University of Illinois Cancer Center and Alas-Wings, Dr. Narjust Florez from Dana-Farber Cancer Institute and Harvard Medical School, and Dr. Kennedy Timothy from MedStar Health and Georgetown University.

In this episode, Dr. Jagmeet Singh of Harvard Medical School and Massachusetts General Hospital and Dr. Sanjay Gandhi of Philips Healthcare Informatics discuss how AI, sensors, and digital tools are reshaping cardiovascular care. They share insights on moving from reactive to proactive care, improving efficiency, and empowering both clinicians and patients in an evolving healthcare landscape.This episode is sponsored by Philips EI.

People under 50 are experiencing higher risk of some cancers. While overall cancer rates are declining, the incidence of 14 cancer types have increased in younger people. Why? It could be related to lifestyle choices, environmental factors, or an individual's genetics. In this episode, host Samantha Laine Perfas speaks with global cancer trend expert Tim Rebbeck, oncologist Kimmie Ng, and epidemiologist Tomotaka Ugai about how people under 50 can best mitigate their cancer risk.

Send us a textDr. David Joseph joins Dr. Michael Koren in part 1 of this 2-part series to discuss his journey into the medical world - with myriad tangents and diversions along the way. Dr. Joseph explores his journey from scrappy teen entrepreneur and freshman MIT researcher and inventor to Harvard-trained anesthesiologist. He talks about his non-standard approach to applying to and studying at Harvard Medical School and how his nontraditional approach to life has led him to interesting places.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Send us a textDr. Kate Lund is a licensed clinical psychologist of 15 years, peak performance coach, best-selling author and TEDx speaker. Her specialized training in medical psychology includes world-renowned Shriners Hospital for Children, Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center, all of which are affiliated with Harvard Medical School. She uses a strengths-based approach to help her clients improve their confidence in school, sports and life while helping them to become more resilient and reach their full potential at all levels. She is also the author of Step Away: The Keys to Resilient Parenting and has a podcast called ”The Optimized Mind.”You can find Dr. Lund online at https://www.katelundspeaks.com/Dyslexia Journey has conversations and explorations to help you support the dyslexic child in your life. Content includes approaches, tips, and interviews with a range of guests from psychologists to educators to people with dyslexia. Increase your understanding and connection with your child as you help them embrace their uniqueness and thrive on this challenging journey!Send us your questions, comments, and guest suggestions to parentingdyslexiajourney@gmail.comAlso check out our YouTube channel! https://www.youtube.com/@ParentingDyslexiaJourney

BrainStorm wants to hear from you! Send us a text.Dr. Rachel Buckley of Mass General Hospital and Harvard Medical School discusses groundbreaking research revealing stark sex differences in Alzheimer's disease with BrainStorm host Meryl Comer. Her studies found that while men and women show similar levels of amyloid protein, women consistently display significantly higher levels of tau. This discovery has sparked a $50 million Welcome Leap Care grant aimed at cutting Alzheimer's lifetime risk among women by half.The episode clarifies widespread confusion about hormone replacement therapy, explaining that the problematic Women's Health Initiative study used outdated hormone formulations on women over 65—far past the optimal window for intervention. Dr. Buckley emphasizes that current evidence supports HRT use within certain parameters and stresses the importance of women advocating for themselves when experiencing perimenopause symptoms like brain fog and sleep disturbances. The research highlights menopause as a critical period that may influence Alzheimer's risk decades later.Support the show

Kimberly Warner is a filmmaker, author, and patient advocate whose work explores what it means to live fully in a body that doesn't always feel well. After studying pre-med and biology at Colorado College and pursuing graduate training in naturopathic and classical Chinese medicine, she veered from a clinical path toward a creative one, trading diagnostics for documentary and turning questions of health into stories of meaning. After developing a rare neurological disorder in 2015, Kimberly turned her artistic focus inward, embracing stillness, intimacy, and relationship as the foundation of her work. In 2019, she launched Unfixed, a media project that now includes award-winning films, limited series, podcasts, memoirs, and live roundtables. Her work has been recognized by PBS, Harvard Medical School, and the Invisible Disabilities Association, among others. Kimberly leads a larger advocacy role within the chronic illness community where she writes and speaks about her own patient experience. She is a member of the Global Advocacy Alliance, the PPAA (Patient and Physician Advocacy Alliance,) is a visiting faculty member with Global Genes, helped create a Course for Clinical Confidence—a medical school certificate course, is on the editorial board of the Journal of Health Design and is an ambassador for VeDA. She is also Life on the Level's Best International Contribution Award, Rainbow Advocacy's Most Innovative Storytelling Award, and the recipient of the Invisible Disabilities Association's Media Impact Award. Her forthcoming memoir, Unfixed: A Memoir of Family, Mystery, and the Currents That Carry You Home, will be published by Empress Editions in October 2025. She lives in rural Oregon with her husband, David, where they tend their small farm between creative projects. When she's not editing films, harvesting calendula, or writing for her beloved Substack audience, she's practicing what she preaches: loosening her grip, staying curious, and letting uncertainty become a place of peace. Links: Preorder memoir: https://a.co/d/185zEos Main website: https://unfixedmedia.com/ Substack (for essays and interviews): https://unfixed.substack.com/ Tax deductible donations: https://www.flipcause.com/secure/cause_pdetails/MTIyMDgx 2025-26 projects * Unbound (short film): https://unfixedmedia.com/unbound * Unsung (short film): https://unfixedmedia.com/unfixed-unsung * Liberation of Being (patient memoir): https://unfixedmedia.com/liberationofbeing * Unfixed: What Time Makes of Us (feature film, focusing on 6 members of the original cast of the Unfixed docuseries)

On episode 244, we welcome Troyen Brennan to discuss the pitfalls of the US healthcare system, the fee-for-service model's implications for patient outcomes, primary care as a more viable alternative, Walmart's failed attempt to establish primary care clinics, Optum's contrasting success, how to incentivize primary care, AI streamlining prior authorizations, increasing government funding and venture capital for primary care, how preventative care keeps patients from falling through the cracks, and why medical professionals tend to dislike the business side of medicine. Troyen A. Brennan is an adjunct professor of health policy and management at the Harvard T. H. Chan School of Public Health. A former professor of medicine at Harvard Medical School and the former chief medical officer at CVS Health, he is the author of The Transformation of American Health Insurance: On the Path to Medicare for All and Just Doctoring: Medical Ethics in the Liberal State. His new book, available October 7, 2025, is called Wonderful and Broken: The Complex Reality of Primary Care in the United States. | Troyen A. Brennan | ► Website | https://www.researchgate.net/scientific-contributions/Troyen-A-Brennan-38805570 ► Linkedin | https://www.linkedin.com/in/troyen-brennan-494bb533 ► Wonderful and Broken Book | https://amzn.to/3KBnjQD Where you can find us: | Seize The Moment Podcast | ► Facebook | https://www.facebook.com/SeizeTheMoment ► Twitter | https://twitter.com/seize_podcast ► Instagram | https://www.instagram.com/seizethemoment ► TikTok | https://www.tiktok.com/@seizethemomentpodcast ► Patreon | https://bit.ly/3xLHTIa  

Osteosarcoma Webinar Series: Alanna Church, MD, Associate Director, Laboratory for Molecular Pediatric Pathology at Boston Children's Hospital, Assistant Professor of Pathology at Harvard Medical School, and Conference Cochair joins us on OsteoBites to discuss insights and higlights from the AACR Special Conference in Cancer Research: Discovery and Innovation in Pediatric Cancer—From Biology to Breakthrough Therapies, September 25-28 in Boston.Dr. Church is currently a Molecular and Pediatric Pathologist at Boston Children's Hospital, where she is a founder and associate medical director of the Laboratory for Molecular Pediatric Pathology (LaMPP). She is an Assistant Professor of Pathology at Harvard Medical School, the Program Director for the Harvard Molecular Genetic Pathology Fellowship, and the incoming Chair of Clinical Practice for the Association for Molecular Pathology. Her clinical and research work focuses on bringing molecular testing to the clinical care of children with cancer. Through institutional projects (the Profile study, GAIN consortium study), she has profiled thousands of children's tumors and has used these results to make real-time impacts on their diagnoses and treatments. She is involved in national initiatives to improve the quality and access to molecular testing for children with cancer, including the NCI-funded Count Me In Study (Dana Farber, Broad Institute), the National Comprehensive Cancer Network, the National Institutes of Health, and the Children's Oncology Group.

Brett Owens, MD, Professor of Orthopaedic Surgery at the Brown University Alpert Medical School in Providence, Rhode Island and Editor-in-Chief of the American Journal of Sports Medicine, and Miho Tanaka, MD, PhD, Director of the Women's Sports Medicine Program at the Massachusetts General Hospital, Associate Professor of Orthopaedic Surgery at Harvard Medical School, and Associate Editor at the American Journal of Sports Medicine, discuss the exciting future of AJSM, challenges in patellofemoral care, women's sports medicine, their secret and not-so-secret talents, and more.

In this episode, Dr. Jagmeet Singh of Harvard Medical School and Massachusetts General Hospital and Dr. Sanjay Gandhi of Philips Healthcare Informatics discuss how AI, sensors, and digital tools are reshaping cardiovascular care. They share insights on moving from reactive to proactive care, improving efficiency, and empowering both clinicians and patients in an evolving healthcare landscape.This episode is sponsored by Philips EI.

I had an instant connection with Kirsten Harrison…we had a “vetting” phone call several weeks before we recorded her episode, and I truly wish I had recorded that conversation and made it a part of this weeks' episode so that you could actually hear that connection! Kirsten and her work are truly inspiring and captivating. Read on, if you would: Dr. Kirsten Harrison has dedicated her career to understanding trauma and guiding survivors through some of life's most difficult psychological and spiritual transitions. With research experience at the UCLA Neuropsychiatric Institute and advanced studies at Georgetown, Pepperdine, and Harvard Medical School, Dr. Harrison brings a wealth of knowledge and clinical skill to her work. Yet, as she shares in this episode, it is the lived experiences of her clients — their creativity, resilience, and will to survive — that have most profoundly shaped her philosophy and practice. As we talked, Kirsten took the conversation deep into the realities of trauma treatment, including her decades of work with PTSD, dissociation, and near-death experiences. She told me not only about her clinical insight and practices, but also her striking view of humanity, and her approach to healing, emphasizing that it is never linear, nor is it confined to a single framework. Instead, it is forged in the bravery of those willing to confront their trauma and fight for their own transformation. A central part of our discussion centered on her groundbreaking book, I, Sean/a: The Story of a Homeless Intersex Woman Who Inspired a Community. Co-authored with Sean/a Smith, the book chronicles the life of an intersex woman living with schizophrenia who endured nearly two decades of homelessness yet never lost her voice or her hope. Through Sean/a's story, Dr. Harrison exposes the failures of outdated medical practices, the destructive force of stigma, and the radical resilience it takes to survive and inspire change. This episode is an invitation to see trauma, healing, and identity through a wider lens. Dr. Harrison's wisdom and candor challenge us all to confront hard truths while also offering a vision of what is possible when compassion and science meet in service of dignity and justice. I truly hope to continue working with Dr. Harrison on widening both of our platforms! An important side note: if you're finding value in these episodes, please take a moment to leave a 5-star rating on your podcast platform. AND, please send me a note of support. I can't tell you how much your emails mean to me—they fuel my passion to keep this podcast going. Here's my email address:   Thank you to all of you who have reached out to me already; and, if you're interested in guesting on the show, please mention that in your email or text, and provide me with a phone number where I can reach you. Please keep those emails and texts coming…I truly look forward to hearing from you! Here are some critically important links that I hope you'll take the time to explore, and where a contribution is requested, please consider doing so!—Thank you!!   (Kennedy Alley: A 100 Mile Journey; GoFundMe link)     (Amazon link to I, Sean/a)   My email address: As mentioned and emphasized, it's time to Normalize the Conversation.™ And please remember to Start by Believing…because we all know someone whose life has been impacted by rape or sexual assault. Thank you for tuning in.

Cancer drugs cost more than ever, yet survival benefits are often modest—and in some cases, patients can't even access the care that already exists. After losing his father, Steve Jobs, to pancreatic cancer, Reed Jobs committed himself to making this the last generation that loses parents to the disease.Reed now leads Yosemite, a venture fund spun out of Emerson Collective in 2023, alongside Investor Matt Bettonville. Yosemite pairs life sciences and digital health investments with a grantmaking model to accelerate cancer research and ensure breakthroughs actually reach patients.We cover:

Join Elizabeth M. Bauer, MD, FACP, FACE, Dipl ABOM, as she interviews Nicholas A. Tritos, MD, DSc, Professor of Clinical Medicine at Harvard Medical School and faculty of the Neuroendocrine Unit/Neuroendocrine and Pituitary Tumor Clinical Center at Massachusetts General Hospital, about his Endocrine Practice article, Impulse Control Disorders in Patients with Hyperprolactinemia on Dopamine Agonist Therapy – How Concerned Should We Be? The conversation explores the prevalence and risk factors for impulse control disorders, underlying biological mechanisms, clinical screening strategies, and approaches to patient counseling and management. Read the full article in the July 2025 issue of Endocrine Practice here: https://doi.org/10.1016/j.eprac.2025.04.018

Who is the authentic you? Some people feel like they remember being an authentic self at some point, and I feel many never experienced it. But I feel we all long to just be comfortable being us. What does that look like? How does it feel? Following is a conversation I had with Dr Thema Bryant. Thema is a clinical psychologist and professor of psychology at Pepperdine University. She's an ordained minister in the African Methodist Episcopal Church. She earned her doctorate from Duke University and completed her postdoctoral training at Harvard Medical School. In the world of academia and psychology she is royalty. When we recorded this conversation, Thema was president-elect of the American Psychological Association. She is now president. Other top psychologists look to her for guidance. Thema has half a million people following her on instagram because she is her authentic self. You'll find her dancing and see her efforts in-play to decolonize traditional psychology and meld science, spirituality and faith, and our very humanity. Thema has a book called, Homecoming: Healing Trauma to Reclaim Your Authentic Self,  and here we take a very base look at the real world issues and hope for today's mental health desires. Find Dr Thema Bryant's book Homecoming anywhere and everywhere, and connect with her at drthema.com. Sign up for your $1/month trial period at shopify.com/kevin Go to shipstation.com and use code KEVIN to start your free trial. Learn more about your ad choices. Visit megaphone.fm/adchoices

Like any card-carrying Italian worth his focaccia, singer Matteo Bocelli says he could eat pasta for breakfast, lunch and dinner! From his home in Tuscany, Matteo tells host Rachel Belle about the super-simple, but deeply delicious, sauce recipe he’s been trying to perfect, inspired by a three-Michelin-star restaurant, and why you should always choose Italian pasta made from ancient grains. You’ve probably heard the tales: A gluten-sensitive American travels to Italy or France, and can magically stuff their face with croissants, baguettes and pasta without any negative consequences. Rachel asks Dr. Alessio Fasano, professor of nutrition and a Celiac and gluten expert and researcher at Harvard Medical School, if, and how, this is possible. Matteo just released his second album, Falling in Love, and if his name sounds familiar, it’s because his dad is Andrea Bocelli, the famous Italian singer. As mentioned in the episode: Watch Rachel Belle & Isaac Mizrahi cook together! Get tickets to Food Fight x America's Test Kitchen in Seattle November 8! Become a Cascade PBS member and support public media! Watch Rachel’s Cascade PBS TV show The Nosh with Rachel Belle! Sign up for Rachel’s (free!) biweekly Cascade PBS newsletter for more food musings! Follow along on Instagram! Order Rachel’s cookbook Open Sesame Support Cascade PBS: https://secure.cascadepublicmedia.org/page/133995/donate/1/See omnystudio.com/listener for privacy information.

Disappointment. Rejection. Failing to meet their goals. It's so tough to watch our kids struggle when they're feeling the discomfort of disappointment. I often call myself “a fixer in recovery that QUITE often relapses”. I have a joy agenda for the people I love. Sometimes my own discomfort over their discomfort leads to a relapse. I jump into full on fixer mode and forget that the growth mostly happens because of the messy human moments. Pain and uncertainty are as much a part of the human experience as success and happiness. It's called the Law of Polarity. Life involves both the good and the bad. What if the real goal of parenting is to help our kiddos build resilience, so they can handle the hard things without losing hope?My guest this time thinks so, and I think she's onto something huge. Dr. Kate Lund is an expert on how to build resilience in ourselves and our kids. Her experience of growing up in a supportive family helped her deal with a painful chronic illness. Now, she teaches parents how to model resilience and prepare kids to navigate the world with confidence.Something clicked while listening?We'd love to talk with you if you want to dig deeper into your family's specific situation. If you're ready to stop guessing and start knowing what works, it might be worth a conversation. https://mastermindparenting.com/live-assessment/ Get all the links, resources, and transcripts here: https://mastermindparenting.com/podcast-329About Randi RubensteinRandi Rubenstein coaches parents raising strong-willed kids. Randi searched endlessly to find the magical resource that would help her own highly sensitive, strong-willed child. (He's now in his 20's, healthy and happy-ish:). She's been passionate about helping other “cycle-breaker” parents like herself for almost two decades.Randi's Web and Social LinksWebsite: https://mastermindparenting.com/Facebook: https://www.facebook.com/mastermindparentingInstagram: https://www.instagram.com/mastermind_parenting/About Dr. LundDr. Kate Lund is a licensed clinical psychologist, resilience expert, author, and host of The Optimized Mind podcast. With specialized training from three Harvard Medical School–affiliated hospitals and more than two decades of clinical practice, she helps parents, athletes, students, and entrepreneurs thrive within their own unique contexts. Dr. Lund is the author of Bounce: Help Your Child Build Resilience and Thrive in School, Sports, and Life, and Step Away: The Keys to Resilient Parenting. Through her writing, speaking, and clinical work, she empowers people to build resilience, manage stress, and unlock their potential.Dr. Lund's Web and Social LinksWebsite: http://www.katelundspeaks.com/ Instagram: https://www.instagram.com/dr_kate_lund/Step Away e-book: https://www.amazon.com/Step-Away-Keys-Resilient-Parenting-ebook/dp/B0FN8D4KBTResources Discussed/LinksOur 12-week Basics Bootcamp program is now...

Chances are, you may be familiar with Dr. Judith Lewis Herman, the legendary psychiatrist, researcher, teacher, and author. Five decades into her esteemed career, Dr. Herman continues to produce innovative work in sexual trauma and Complex PTSD. But you might not know Judith Herman, the daughter, mother, grandmother, and activist. On this episode of Transforming Trauma, Emily Ruth is honored to welcome back Dr. Judith Lewis Herman for an illuminating conversation on the life experiences and enduring connections that have shaped her public and private life. The pair also explores the positive impact that activism and affiliation with others can have on those who've experienced trauma, and why adopting an active coping strategy is one of the best predictors of recovery.  About Judith Lewis Herman, M.D.: Judith Lewis Herman, M.D., is Professor of Psychiatry (part time) at Harvard Medical School. For thirty years, until she retired, she was Director of Training at the Victims of Violence Program at The Cambridge Hospital, Cambridge, MA. Dr. Herman is the author of the award-winning books: Father-Daughter Incest (Harvard University Press, 1981) and Trauma and Recovery (Basic Books, 1992). To read the full show notes and discover more resources, visit https://complextraumatrainingcenter.com/transformingtrauma SPACE: SPACE is an Inner Development Program of Support and Self-Discovery for Therapists on the Personal, Interpersonal, and Transpersonal Levels offered by the Complex Trauma Training Center. This experiential learning program offers an immersive group experience designed to cultivate space for self-care, community support, and deepening vitality in our professional role as therapists. Learn more about how to join. *** The Complex Trauma Training Center: https://complextraumatrainingcenter.com View upcoming trainings: https://complextraumatrainingcenter.com/schedule/ *** The Complex Trauma Training Center (CTTC) is a professional organization providing clinical training, education, consultation, and mentorship for psychotherapists and mental health professionals working with individuals and communities impacted by Adverse Childhood Experiences (ACEs) and Complex Trauma (C-PTSD). CTTC provides NARM® Therapist and NARM® Master Therapist Training programs, as well as ongoing monthly groups in support of those learning NARM. CTTC offers a depth-oriented professional community for those seeking a supportive network of therapists focused on three levels of shared human experience: personal, interpersonal & transpersonal. The Transforming Trauma podcast embodies the spirit of CTTC – best described by its three keywords: depth, connection, and heart - and offers guidance to those interested in effective, transformational trauma-informed care. We want to connect with you! Facebook @complextraumatrainingcenter Instagram @cttc_training LinkedIn YouTube

PURCHASE THIS PODCOURSE! If you are a therapist or counselor looking for continuing education, check out my NBCC Approved $5 Podcourses and other continuing education offerings.Plus, get your first Podcourse half off. In this Podcourse episode, I sit down with Dr. Timothy Davis, a psychologist who has spent his career working with what he calls “challenging boys.” He shares how his background, from academic research to volunteer firefighting, inspired a practical framework that helps parents manage meltdowns, build resilience, and strengthen their connection with their child. Together, we explore how therapists can support parents in creating effective Emergency Plans, identifying skill deficits in emotion regulation and executive functioning, and applying family systems principles to improve family dynamics. Our hope is that you'll walk away with fresh strategies you can integrate into your clinical work right away and you can also earn one NBCC continuing education contact hour by completing this Podcourse.

In this fascinating episode with Will Ahmed, founder of WHOOP (you can click here to get 1 month free on your membership), you’ll get to discover how his company is redefining health tracking through continuous 24/7 physiological monitoring, actionable coaching, and innovations like ECG readings and noninvasive blood pressure insights. Will Ahmed is the Founder and CEO of WHOOP, which has developed next-generation wearable technology for optimizing human performance and health. WHOOP members include professional athletes, Fortune 500 CEOs, fitness enthusiasts, military personnel, frontline workers, and a broad range of people looking to improve their performance. Ahmed is a member of the Board of Fellows of Harvard Medical School, where he provides counsel to the Dean and faculty on topics related to the strength and health of the institution. Ahmed was named to the 2021 Sports Business Journal 40 Under 40 list as well as 2020 Fortune 40 Under 40 Healthcare list and previously named to the Forbes 30 Under 30 and Boston Business Journal’s 40 Under 40. Ahmed founded WHOOP as a student at Harvard College, where he captained the Men’s Varsity Squash Team and graduated with an A.B. in government. WHOOP, the human performance company, offers a wearable health and fitness coach to help people achieve their goals. The WHOOP membership provides best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, training, and health. WHOOP serves professional athletes, Fortune 500 CEOs, executives, fitness enthusiasts, military personnel, frontline workers, and anyone looking to improve their performance. Discount Codes: You can click here to get 1 month of WHOOP for free (membership only). Full show notes: bengreenfieldlife.com/WHOOP5 Episode Sponsors: LVLUP Health: I trust and recommend LVLUP Health for your peptide needs as they third-party test every single batch of their peptides to ensure you’re getting exactly what you pay for and the results you’re after! Head over to lvluphealth.com/BGL and use code BEN15 for a special discount on their game-changing range of products. Ketone-IQ: Ketone-IQ delivers science-backed performance fuel that increases power output by 19%, reduces fatigue by 10%, and naturally boosts EPO production for better oxygen delivery—trusted by elite athletes like Jon Jones and Olympic champions. Save 30% on your subscription plus get a free gift with your second shipment at Ketone.com/BENG. Quantum Upgrade: Recent research has revealed that the Quantum Upgrade was able to increase ATP production by a jaw-dropping 20–25% in human cells. Unlock a 15-day free trial with the code BEN15 at quantumupgrade.io. MASA Chips: Introducing the best guilt-free snack on the market: classic, seed oil free tortilla chips with only 3 natural ingredients. Go to masachips.com/greenfield and get 25% off your first order! Timeline Nutrition: Give your cells new life with high-performance products powered by Mitopure, Timeline's powerful ingredient that unlocks a precise dose of the rare Urolithin A molecule and promotes healthy aging. Go to shop.timeline.com/BEN and use code BEN to get 20% off your order.See omnystudio.com/listener for privacy information.

Dr. Diane Hennacy is a Johns Hopkins-trained neuropsychiatrist, author, public speaker, and independent researcher exploring the intersection of science, consciousness, and anomalous phenomena like telepathy and psychic abilities. With over 30 years of clinical experience, she has served on the faculty at Harvard Medical School and participated in think tanks on human consciousness at the Salk Institute. Hennacy's groundbreaking work bridges rigorous scientific inquiry with mysteries of the mind, including studies on autism, savant syndrome, and potential links to extrasensory perception (ESP). Her bestselling book, The ESP Enigma: The Scientific Case for Psychic Phenomena (2009), presents evidence from neuroscience, quantum physics, and case studies to explain psychic experiences. A student of ancient wisdom traditions and an award-winning clinician, she has spoken at international scientific conferences, the United Nations, and venues like TEDx, advocating for open-minded exploration of human potential and consciousness. Hennacy, who also held the title of Miss Oregon Senior America 2017, continues her research through the Hennacy Institute for Consciousness Research, emphasizing integrative medicine and the evolution of human awareness. Shawn Ryan Show Sponsors: https://americanfinancing.net/srs NMLS 182334, nmlsconsumeraccess.org. APR for rates in the 5s start at 6.327% for well qualified borrowers. Call 866-781-8900, for details about credit costs and terms. https://tryarmra.com/srs https://aura.com/srs https://betterhelp.com/srs This episode is sponsored. Give online therapy a try at betterhelp.com/srs and get on your way to being your best self. https://bubsnaturals.com – USE CODE SHAWN https://shawnlikesgold.com https://mypatriotsupply.com/srs https://patriotmobile.com/srs https://ROKA.com – USE CODE SRS https://shopify.com/srs https://trueclassic.com/srs https://USCCA.com/srs Dr. Diane Hennacy Links: Website - https://drdianehennacy.com X - https://x.com/drhennacy41125 Buy The ESP Enigma - https://drdianehennacy.com/purchase-esp-enigma Learn more about your ad choices. Visit podcastchoices.com/adchoices

Many psychiatric labels—like bipolar disorder and schizophrenia—can obscure underlying biology, and symptom checklists often fail to explain or heal what's really going on. Emerging evidence reframes mental illness as a problem of brain energy, mitochondria, and inflammation—shaped by insulin signaling, circadian rhythm disruption, the gut–brain axis, toxins, infections, and nutrient status. Metabolic interventions such as ketogenic nutrition, already established for epilepsy, show promise for rebalancing neurotransmitters, lowering neuroinflammation, and improving overall brain function. With depression now a leading cause of disability, shifting from “manage the symptoms” to “fix the biology” could dramatically improve outcomes where standard drugs fall short. In this episode, Dr. Christopher Palmer, Dr. Todd LePine, Dr. Iain Campbell and I explore how rethinking mental illness as a metabolic and inflammatory disorder of the brain—rather than just a chemical imbalance—could transform the treatment and prevention of conditions like depression, bipolar disorder, and schizophrenia. Dr. Chris Palmer is a psychiatrist and researcher working at the interface of metabolism and mental health. He is the Director of the Department of Postgraduate and Continuing Education at McLean Hospital and an Assistant Professor of Psychiatry at Harvard Medical School. For over 25 years, he has held leadership roles in psychiatric education, conducted research, and worked with people who have treatment-resistant mental illnesses. He has been pioneering the use of the medical ketogenic diet in the treatment of psychiatric disorders - conducting research in this area, treating patients, writing, and speaking around the world on this topic. More broadly, he is interested in the roles of metabolism and metabolic interventions on brain health. Dr. Todd LePine graduated from Dartmouth Medical School and is Board Certified in Internal Medicine, specializing in Integrative Functional Medicine. He is an Institute for Functional Medicine Certified Practitioner. Prior to joining The UltraWellness Center, he worked as a physician at Canyon Ranch in Lenox, MA, for 10 years. Dr. LePine's focus at The UltraWellness Center is to help his patients achieve optimal health and vitality by restoring the natural balance to both the mind and the body. His areas of interest include optimal aging, bio-detoxification, functional gastrointestinal health, systemic inflammation, autoimmune disorders, and the neurobiology of mood and cognitive disorders.  Dr. lain Campbell is the first academic research fellow to specialise in Metabolic Psychiatry as the Baszucki Research Fellow in Metabolic Psychiatry at the University of Edinburgh. He has a PhD in Global Health from the University of Edinburgh and is a principal investigator on a pilot trial of a ketogenic diet for bipolar disorder. He is a workstream lead and co-investigator on the first publicly funded research hub for Metabolic Psychiatry, the UKRI Medical Research Council Hub for Metabolic Psychiatry at the University of Edinburgh. His research in metabolic psychiatry has been published in Nature press journals Molecular Psychiatry and Translational Psychiatry and presented at Mayo Clinic Grand Rounds and The Royal College of Psychiatrists International Congress.  This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN to save 15%. Full-length episodes can be found here:A Harvard Psychiatrist Rethinks Mental Health As A Metabolic Disease Is Brain Inflammation The Cause of Depression, Dementia, ADD, And Autism? A Functional Medicine Approach To Neuroinflammation Is Bipolar Disorder Really a Diet Problem?

Dietary supplements are big business, with one recent estimate showing the industry is worth almost $64 billion in the United States alone. Take a casual scroll through your social media and you'll find influencers hawking all kinds of supplements. But how effective are they? How are they regulated? And why are these “natural” remedies so appealing to millions of Americans? To size up the science and culture of supplements, Host Flora Lichtman talks with supplement researcher Pieter Cohen, and Colleen Derkatch, author of Why Wellness Sells: Natural Health in a Pharmaceutical Culture. Guests: Dr. Pieter Cohen is an Associate Professor of Medicine at Harvard Medical School and an internist at the Cambridge Health Alliance where he leads the Supplement Research Program. Dr. Colleen Derkatch is the author of Why Wellness Sells: Natural Health in a Pharmaceutical Culture and professor of rhetoric at Toronto Metropolitan University.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.